vs
Emergent BioSolutions Inc.（EBS）与Resolute Holdings Management, Inc.（RHLD）财务数据对比。点击上方公司名可切换其他公司
Emergent BioSolutions Inc.的季度营收约是Resolute Holdings Management, Inc.的1.3倍（$148.7M vs $117.7M），Resolute Holdings Management, Inc.净利率更高（-1.5% vs -36.7%，领先35.3%），Resolute Holdings Management, Inc.自由现金流更多（$189.2M vs $73.8M）
Emergent BioSolutions是一家总部位于美国马里兰州盖瑟斯堡的跨国专业生物制药企业，公司专注于开发针对传染病及阿片类药物过量的疫苗与抗体疗法，同时还为生物防御领域提供相关医疗设备支持。
Resolute Holdings Management, Inc.是一家澳大利亚矿业企业，核心业务布局于非洲地区，目前运营两座金矿，分别为位于马里的 Syama 金矿和塞内加尔的 Mako 金矿，专注于黄金资源的勘探、开采及相关运营管理工作。
EBS vs RHLD — 直观对比
营收规模更大
EBS
是对方的1.3倍
$117.7M
净利率更高
RHLD
高出35.3%
-36.7%
自由现金流更多
RHLD
多$115.4M
$73.8M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $148.7M | $117.7M |
| 净利润 | $-54.6M | $-1.7M |
| 毛利率 | 42.9% | 55.7% |
| 营业利润率 | -18.8% | 30.2% |
| 净利率 | -36.7% | -1.5% |
| 营收同比 | -23.6% | — |
| 净利润同比 | -74.4% | — |
| 每股收益（稀释后） | $-0.95 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBSRHLD
| Q4 25 | $148.7M | $117.7M | ||
| Q3 25 | $231.1M | $120.9M | ||
| Q2 25 | $140.9M | $119.6M | ||
| Q1 25 | $222.2M | $103.9M | ||
| Q4 24 | $194.7M | — | ||
| Q3 24 | $293.8M | — | ||
| Q2 24 | $254.7M | — | ||
| Q1 24 | $300.4M | — |
净利润EBSRHLD
| Q4 25 | $-54.6M | $-1.7M | ||
| Q3 25 | $51.2M | $-231.0K | ||
| Q2 25 | $-12.0M | $-611.0K | ||
| Q1 25 | $68.0M | $-3.4M | ||
| Q4 24 | $-31.3M | — | ||
| Q3 24 | $114.8M | — | ||
| Q2 24 | $-283.1M | — | ||
| Q1 24 | $9.0M | — |
毛利率EBSRHLD
| Q4 25 | 42.9% | 55.7% | ||
| Q3 25 | 62.8% | 59.0% | ||
| Q2 25 | 52.5% | 57.5% | ||
| Q1 25 | 60.2% | 52.5% | ||
| Q4 24 | 39.4% | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | -18.8% | — | ||
| Q1 24 | 49.2% | — |
营业利润率EBSRHLD
| Q4 25 | -18.8% | 30.2% | ||
| Q3 25 | 33.1% | 34.3% | ||
| Q2 25 | 1.1% | 34.0% | ||
| Q1 25 | 22.5% | 24.7% | ||
| Q4 24 | -4.9% | — | ||
| Q3 24 | 22.0% | — | ||
| Q2 24 | -79.9% | — | ||
| Q1 24 | 13.2% | — |
净利率EBSRHLD
| Q4 25 | -36.7% | -1.5% | ||
| Q3 25 | 22.2% | -0.2% | ||
| Q2 25 | -8.5% | -0.5% | ||
| Q1 25 | 30.6% | -3.2% | ||
| Q4 24 | -16.1% | — | ||
| Q3 24 | 39.1% | — | ||
| Q2 24 | -111.2% | — | ||
| Q1 24 | 3.0% | — |
每股收益（稀释后）EBSRHLD
| Q4 25 | $-0.95 | $-0.20 | ||
| Q3 25 | $0.91 | $-0.03 | ||
| Q2 25 | $-0.22 | $-0.07 | ||
| Q1 25 | $1.19 | $-0.39 | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $2.06 | — | ||
| Q2 24 | $-5.38 | — | ||
| Q1 24 | $0.17 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $205.4M | $205.5M |
| 总债务越低越好 | $589.7M | $169.8M |
| 股东权益账面价值 | $522.6M | $6.5M |
| 总资产 | $1.3B | $333.4M |
| 负债/权益比越低杠杆越低 | 1.13× | 26.03× |
8季度趋势，按日历期对齐
现金及短期投资EBSRHLD
| Q4 25 | $205.4M | $205.5M | ||
| Q3 25 | $245.5M | $148.0M | ||
| Q2 25 | $267.3M | $99.9M | ||
| Q1 25 | $149.1M | $71.0M | ||
| Q4 24 | $99.5M | — | ||
| Q3 24 | $149.9M | — | ||
| Q2 24 | $69.7M | — | ||
| Q1 24 | $78.5M | — |
总债务EBSRHLD
| Q4 25 | $589.7M | $169.8M | ||
| Q3 25 | $693.1M | $173.4M | ||
| Q2 25 | $700.0M | $177.1M | ||
| Q1 25 | $700.0M | $180.7M | ||
| Q4 24 | $700.0M | — | ||
| Q3 24 | $700.8M | — | ||
| Q2 24 | $863.8M | — | ||
| Q1 24 | $909.2M | — |
股东权益EBSRHLD
| Q4 25 | $522.6M | $6.5M | ||
| Q3 25 | $582.5M | $10.8M | ||
| Q2 25 | $536.2M | $9.6M | ||
| Q1 25 | $552.7M | $8.9M | ||
| Q4 24 | $482.8M | — | ||
| Q3 24 | $508.4M | — | ||
| Q2 24 | $386.3M | — | ||
| Q1 24 | $663.9M | — |
总资产EBSRHLD
| Q4 25 | $1.3B | $333.4M | ||
| Q3 25 | $1.5B | $293.2M | ||
| Q2 25 | $1.4B | $253.3M | ||
| Q1 25 | $1.4B | $214.3M | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.8B | — |
负债/权益比EBSRHLD
| Q4 25 | 1.13× | 26.03× | ||
| Q3 25 | 1.19× | 16.01× | ||
| Q2 25 | 1.31× | 18.42× | ||
| Q1 25 | 1.27× | 20.38× | ||
| Q4 24 | 1.45× | — | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | 2.24× | — | ||
| Q1 24 | 1.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $77.7M | $196.1M |
| 自由现金流经营现金流 - 资本支出 | $73.8M | $189.2M |
| 自由现金流率自由现金流/营收 | 49.6% | 160.8% |
| 资本支出强度资本支出/营收 | 2.6% | 5.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $156.8M | $313.2M |
8季度趋势，按日历期对齐
经营现金流EBSRHLD
| Q4 25 | $77.7M | $196.1M | ||
| Q3 25 | $-2.3M | $59.6M | ||
| Q2 25 | $106.4M | $48.9M | ||
| Q1 25 | $-11.2M | $18.4M | ||
| Q4 24 | $-79.9M | — | ||
| Q3 24 | $153.7M | — | ||
| Q2 24 | $47.5M | — | ||
| Q1 24 | $-62.6M | — |
自由现金流EBSRHLD
| Q4 25 | $73.8M | $189.2M | ||
| Q3 25 | $-5.7M | $58.6M | ||
| Q2 25 | $103.5M | $47.5M | ||
| Q1 25 | $-14.8M | $17.8M | ||
| Q4 24 | $-81.6M | — | ||
| Q3 24 | $147.9M | — | ||
| Q2 24 | $42.9M | — | ||
| Q1 24 | $-73.4M | — |
自由现金流率EBSRHLD
| Q4 25 | 49.6% | 160.8% | ||
| Q3 25 | -2.5% | 48.5% | ||
| Q2 25 | 73.5% | 39.7% | ||
| Q1 25 | -6.7% | 17.1% | ||
| Q4 24 | -41.9% | — | ||
| Q3 24 | 50.3% | — | ||
| Q2 24 | 16.8% | — | ||
| Q1 24 | -24.4% | — |
资本支出强度EBSRHLD
| Q4 25 | 2.6% | 5.8% | ||
| Q3 25 | 1.5% | 0.8% | ||
| Q2 25 | 2.1% | 1.2% | ||
| Q1 25 | 1.6% | 0.6% | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 3.6% | — |
现金转化率EBSRHLD
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.16× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -6.96× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EBS
| Medical Countermeasures MCM Product | $99.2M | 67% |
| Commercial Products Segment | $38.4M | 26% |
| All Other Revenue | $11.1M | 7% |
RHLD
暂无分部数据
